DILANTIN-125 SUSPENSION 125 MG / 5 ML
PHENYTOIN : 125 MG / 5 ML · DIN 00023450 · BGP PHARMA ULC
Health Canada status: CANCELLED POST MARKET
What is DILANTIN-125 SUSPENSION?
DILANTIN-125 SUSPENSION 125 MG / 5 ML contains PHENYTOIN : 125 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 00023450, held by BGP PHARMA ULC, supplied as SUSPENSION for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-Dec-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00023450 |
|---|---|
| Brand name | DILANTIN-125 SUSPENSION |
| Generic / active ingredient | PHENYTOIN : 125 MG / 5 ML |
| Manufacturer | BGP PHARMA ULC |
| Strength | 125 MG / 5 ML |
| Dosage form | SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AB02 PHENYTOIN |
| AHFS class | 28:12.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-Dec-2025 |
| Original market date | 1953-12-31 00:00:00 |
Is PHENYTOIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N03AB02 PHENYTOIN. 7 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DILANTIN | 100 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 00022780 |
| DILANTIN | 30 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 00022772 |
| DILANTIN INFATABS | 50 MG | TABLET (CHEWABLE) | BGP PHARMA ULC | MARKETED | DIN 00023698 |
| PHENYTOIN SODIUM | 100 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 02460912 |
| PHENYTOIN SODIUM INJECTION USP | 50 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02431378 |
| PHENYTOIN SODIUM INJECTION USP | 50 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00780626 |
| TARO-PHENYTOIN | 125 MG / 5 ML | SUSPENSION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02250896 |
| DILANTIN INJ 50MG/ML | 250 MG / 5 ML | LIQUID | PARKE-DAVIS DIVISION, WARNER-LAMBERT CANADA INC. | CANCELLED POST MARKET | DIN 00245453 |
| DILANTIN-30 SUSPENSION | 30 MG / 5 ML | SUSPENSION | BGP PHARMA ULC | CANCELLED POST MARKET | DIN 00023442 |
| NOVO-PHENYTOIN CAP 100MG | 100 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 00037435 |
Who else supplies PHENYTOIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PHENYTOIN appears in 35 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.